Promethera Biosciences SA, a Belgian biotechnology company developing stem cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired liver diseases with high unmet medical needs, has announced that Dr John Tchelingerian, Chief Executive Officer, Promethera, will present and participate at two forthcoming leading international biotech conferences.
The conferences are BioEquity Europe 2016 in Copenhagen, Denmark and the World Stem Cell congress 2016 in London, UK.
John Tchelingerian will present at the 17th BioEquity Europe 2016 in Copenhagen, Denmark on 10 May, room 3 at 5:40 PM CEST. John will provide updates about the development of Promethera’s product pipeline as well as providing important information about the company following their acquisition of the key assets of their most advanced competitor, the liver cell therapy company Cytonet and what this means for the strategy of Promethera.
BioEquity Europe is designed for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
John Tchelingerian will also participate at a roundtable at the World Stem Cell congress 2016 at 11.25 AM on 19 May, at the Business Design Centre in London. The roundtable will be entitled ‘Biotech updates: From head-to-toe.’ The roundtable is set to provide updates on the latest biotech advances in cell therapy. Promethera Biosciences has been selected to represent the liver cell therapy area.
“Since 2015, and even more so in 2016, Promethera has driven forward, following the timescale of the new strategic plan I designed when becoming CEO in 2015. This has culminated in the acquisition of the key assets of Cytonet. This adds a pre-commercialization product, Heparesc to our existing pipeline with HepaStem and H2Stem, as well as a US presence for Promethera in Durham (NC, USA) and additional senior management experience and capabilities,” said Dr John Tchelingerian, CEO of Promethera.
“It is of value for us now to update the market and investors on how we plan to continue to move forward to deliver critically needed therapies in the liver area to patients as soon as possible,” he added.